HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
HC Wainwright & Co. 繼續買入 protagonist therapeutics 股票，將價格目標上調至$40
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $38 to $40.
HC韋恩賴特公司的分析師Douglas Tsao認爲Protagonist Therapeutics（NASDAQ:PTGX）值得買入，並將價格目標從38美元提高到40美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。